Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients

(American Association for Cancer Research) With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent.

from EurekAlert! - Social and Behavioral Science https://ift.tt/2JFZ13C